RE: Court back log6 Jan 2022 18:07
I acknowledge that the court are frustrating, but Burford potential is still strong.
Looking at Portfolio at mid-year having possibly increased by year end to $3.3m, and even assuming a slower case resolution rate averaging around 4.5 years until CV19 delays resolved gives annual gross income of $917m, assuming profit to cost ratio of 125%, (longer resolving cases result in higher returns as per Nov 2021 presentation). Then deduct Op expenses $80m, financing of $40m, and incentive costs of 10% $92m, being total costs of $212m, giving PBT of $705m and tax at low teens percentage, say 15% resulting in PAT of $599m. In GBP per share £2.01p, and PE ratio maybe 15 gives share price of £30.
Don’t forget further potential from performance fees for assets under management and Petersen of course.